FHND9041

The main study objectives are: 1) to investigate the distribution of [14C]FHND9041 in whole blood and plasma and the pharmacokinetics of total radioactivity in plasma after a single oral administration of [14C]FHND9041 to male healthy subjects; 2) to quantitatively analyze the total radioactivity in excreta after oral administration of [14C]FHND9041 to male healthy subjects, and obtain the cumulative excretion rate and main excretion pathway of radioactivity in the human body; 3) to quantitatively analyze the concentration of FHND9041 and its main metabolites (if applicable) in plasma using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, and obtain the pharmacokinetic parameters of FHND9041 and its main metabolites (if applicable); 4) to identify the main metabolites in the human body after oral administration of [14C]FHND9041 to male healthy subjects, and to determine the main biotransformation pathways and main metabolites (close to or greater than 10% of the total radioactivity AUC). Secondary study objectives: to evaluate the safety of [14C]FHND9041 in healthy subjects after a single dose.